Health-related Quality of Life in Intermediate- or High-risk Patients Treated with Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer: A Randomized, Phase III SPCG-13 Study

Miikka Lehtonen; Jorma Sormunen; Marie Hjälm-Eriksson; Camilla Thellenberg-Karlsson; Teppo Huttunen; Claes Ginman; Pirkko Liisa Kellokumpu-Lehtinen

doi:10.21873/anticanres.15460

Health-related Quality of Life in Intermediate- or High-risk Patients Treated with Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer: A Randomized, Phase III SPCG-13 Study

Miikka Lehtonen^*
, Jorma Sormunen
, Marie Hjälm-Eriksson
, Camilla Thellenberg-Karlsson
, Teppo Huttunen
, Claes Ginman
, Pirkko Liisa Kellokumpu-Lehtinen

^*Corresponding author for this work

Research output: Contribution to journal › Article › Scientific › peer-review

Abstract

Background/Aim: The goal of this study was to investigate whether health-related quality of life (HRQoL) was affected in patients with high- or intermediate-risk localized prostate cancer treated with docetaxel following radiation therapy (RT). Patients and Methods: A total of 376 patients treated with RT and androgen deprivation were randomized to receive 6 cycles of docetaxel 75 mg/m² (N=188, Arm A) or surveillance (N=188, Arm B). FACT-P HRQoL questionnaires were gathered at baseline, six months and 1, 2 and 4 years after randomization. The data were analysed using analysis of covariance. Results: FACT-P scores decreased in Arm A at the end of treatment and remained unchanged in Arm B (p<0.0001). The HRQoL scores in Arm A matched Arm B in the 1-year follow-up (p=0.0528) and remained similar in further follow-up. Conclusion: Docetaxel transiently decreased HRQoL during chemotherapy but not after treatment for up to four years of follow-up.

Original language	English
Pages (from-to)	87-92
Number of pages	6
Journal	Anticancer Research
Volume	42
Issue number	1
Early online date	Dec 2021
DOIs	https://doi.org/10.21873/anticanres.15460
Publication status	Published - 2022
Publication type	A1 Journal article-refereed

Funding

We would like to thank all the investigators, study coordinators and nurses within the SPCG-13 participating centres: Karolinska University Hospital, Uppsala University Hospital, Örebro University Hospital, Karlstad, Sundsvall, Eskilstuna, Växjö and Jönköping Hospitals in Sweden and Tampere University Hospital, Hospitals in Lahti and Seinäjoki in Finland. We would also like to thank all patients who participated in the SPCG-13 trial, their families and Sanofi for their financial contribution to the SPCG-13 trial. The SPCG-13 investigator-sponsored trial received funding from Sanofi. This study was also partly supported by the Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospital. The funders had no impact on the study design, collection of data, data analysis, interpretation of results or contents of the article.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Docetaxel
Prostate cancer
Quality of life
Radiotherapy

Publication forum classification

Publication forum level 1

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.21873/anticanres.15460

Fingerprint

Dive into the research topics of 'Health-related Quality of Life in Intermediate- or High-risk Patients Treated with Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer: A Randomized, Phase III SPCG-13 Study'. Together they form a unique fingerprint.

Cite this

Lehtonen, M., Sormunen, J., Hjälm-Eriksson, M., Thellenberg-Karlsson, C., Huttunen, T., Ginman, C., & Kellokumpu-Lehtinen, P. L. (2022). Health-related Quality of Life in Intermediate- or High-risk Patients Treated with Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer: A Randomized, Phase III SPCG-13 Study. Anticancer Research, 42(1), 87-92. https://doi.org/10.21873/anticanres.15460

@article{3b5c86acba5048258292ded5ae23d73c,

title = "Health-related Quality of Life in Intermediate- or High-risk Patients Treated with Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer: A Randomized, Phase III SPCG-13 Study",

abstract = "Background/Aim: The goal of this study was to investigate whether health-related quality of life (HRQoL) was affected in patients with high- or intermediate-risk localized prostate cancer treated with docetaxel following radiation therapy (RT). Patients and Methods: A total of 376 patients treated with RT and androgen deprivation were randomized to receive 6 cycles of docetaxel 75 mg/m2 (N=188, Arm A) or surveillance (N=188, Arm B). FACT-P HRQoL questionnaires were gathered at baseline, six months and 1, 2 and 4 years after randomization. The data were analysed using analysis of covariance. Results: FACT-P scores decreased in Arm A at the end of treatment and remained unchanged in Arm B (p<0.0001). The HRQoL scores in Arm A matched Arm B in the 1-year follow-up (p=0.0528) and remained similar in further follow-up. Conclusion: Docetaxel transiently decreased HRQoL during chemotherapy but not after treatment for up to four years of follow-up.",

keywords = "Docetaxel, Prostate cancer, Quality of life, Radiotherapy",

author = "Miikka Lehtonen and Jorma Sormunen and Marie Hj{\"a}lm-Eriksson and Camilla Thellenberg-Karlsson and Teppo Huttunen and Claes Ginman and Kellokumpu-Lehtinen, \{Pirkko Liisa\}",

note = "Funding Information: We would like to thank all the investigators, study coordinators and nurses within the SPCG-13 participating centres: Karolinska University Hospital, Uppsala University Hospital, {\"O}rebro University Hospital, Karlstad, Sundsvall, Eskilstuna, V{\"a}xj{\"o} and J{\"o}nk{\"o}ping Hospitals in Sweden and Tampere University Hospital, Hospitals in Lahti and Sein{\"a}joki in Finland. We would also like to thank all patients who participated in the SPCG-13 trial, their families and Sanofi for their financial contribution to the SPCG-13 trial. The SPCG-13 investigator-sponsored trial received funding from Sanofi. This study was also partly supported by the Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospital. The funders had no impact on the study design, collection of data, data analysis, interpretation of results or contents of the article. Publisher Copyright: {\textcopyright} 2022 International Institute of Anticancer Research. All rights reserved.",

year = "2022",

doi = "10.21873/anticanres.15460",

language = "English",

volume = "42",

pages = "87--92",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "1",

}

Lehtonen, M, Sormunen, J, Hjälm-Eriksson, M, Thellenberg-Karlsson, C, Huttunen, T, Ginman, C & Kellokumpu-Lehtinen, PL 2022, 'Health-related Quality of Life in Intermediate- or High-risk Patients Treated with Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer: A Randomized, Phase III SPCG-13 Study', Anticancer Research, vol. 42, no. 1, pp. 87-92. https://doi.org/10.21873/anticanres.15460

Health-related Quality of Life in Intermediate- or High-risk Patients Treated with Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer: A Randomized, Phase III SPCG-13 Study. / Lehtonen, Miikka; Sormunen, Jorma; Hjälm-Eriksson, Marie et al.
In: Anticancer Research, Vol. 42, No. 1, 2022, p. 87-92.

Research output: Contribution to journal › Article › Scientific › peer-review

TY - JOUR

T1 - Health-related Quality of Life in Intermediate- or High-risk Patients Treated with Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer

T2 - A Randomized, Phase III SPCG-13 Study

AU - Lehtonen, Miikka

AU - Sormunen, Jorma

AU - Hjälm-Eriksson, Marie

AU - Thellenberg-Karlsson, Camilla

AU - Huttunen, Teppo

AU - Ginman, Claes

AU - Kellokumpu-Lehtinen, Pirkko Liisa

N1 - Funding Information: We would like to thank all the investigators, study coordinators and nurses within the SPCG-13 participating centres: Karolinska University Hospital, Uppsala University Hospital, Örebro University Hospital, Karlstad, Sundsvall, Eskilstuna, Växjö and Jönköping Hospitals in Sweden and Tampere University Hospital, Hospitals in Lahti and Seinäjoki in Finland. We would also like to thank all patients who participated in the SPCG-13 trial, their families and Sanofi for their financial contribution to the SPCG-13 trial. The SPCG-13 investigator-sponsored trial received funding from Sanofi. This study was also partly supported by the Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospital. The funders had no impact on the study design, collection of data, data analysis, interpretation of results or contents of the article. Publisher Copyright: © 2022 International Institute of Anticancer Research. All rights reserved.

PY - 2022

Y1 - 2022

N2 - Background/Aim: The goal of this study was to investigate whether health-related quality of life (HRQoL) was affected in patients with high- or intermediate-risk localized prostate cancer treated with docetaxel following radiation therapy (RT). Patients and Methods: A total of 376 patients treated with RT and androgen deprivation were randomized to receive 6 cycles of docetaxel 75 mg/m2 (N=188, Arm A) or surveillance (N=188, Arm B). FACT-P HRQoL questionnaires were gathered at baseline, six months and 1, 2 and 4 years after randomization. The data were analysed using analysis of covariance. Results: FACT-P scores decreased in Arm A at the end of treatment and remained unchanged in Arm B (p<0.0001). The HRQoL scores in Arm A matched Arm B in the 1-year follow-up (p=0.0528) and remained similar in further follow-up. Conclusion: Docetaxel transiently decreased HRQoL during chemotherapy but not after treatment for up to four years of follow-up.

AB - Background/Aim: The goal of this study was to investigate whether health-related quality of life (HRQoL) was affected in patients with high- or intermediate-risk localized prostate cancer treated with docetaxel following radiation therapy (RT). Patients and Methods: A total of 376 patients treated with RT and androgen deprivation were randomized to receive 6 cycles of docetaxel 75 mg/m2 (N=188, Arm A) or surveillance (N=188, Arm B). FACT-P HRQoL questionnaires were gathered at baseline, six months and 1, 2 and 4 years after randomization. The data were analysed using analysis of covariance. Results: FACT-P scores decreased in Arm A at the end of treatment and remained unchanged in Arm B (p<0.0001). The HRQoL scores in Arm A matched Arm B in the 1-year follow-up (p=0.0528) and remained similar in further follow-up. Conclusion: Docetaxel transiently decreased HRQoL during chemotherapy but not after treatment for up to four years of follow-up.

KW - Docetaxel

KW - Prostate cancer

KW - Quality of life

KW - Radiotherapy

U2 - 10.21873/anticanres.15460

DO - 10.21873/anticanres.15460

M3 - Article

AN - SCOPUS:85121979782

SN - 0250-7005

VL - 42

SP - 87

EP - 92

JO - Anticancer Research

JF - Anticancer Research

IS - 1

ER -

Lehtonen M, Sormunen J, Hjälm-Eriksson M, Thellenberg-Karlsson C, Huttunen T, Ginman C et al. Health-related Quality of Life in Intermediate- or High-risk Patients Treated with Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer: A Randomized, Phase III SPCG-13 Study. Anticancer Research. 2022;42(1):87-92. Epub 2021 Dec. doi: 10.21873/anticanres.15460